Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome (Q24244169)

5

object named as

Niek de Wit

0 references

author name string

A Otto Quartero

1

0 references

Villy Meiniche-Schmidt

2

0 references

Gregory Rubin

Cochrane Database of Systematic Reviews

4

0 references

publication date

20 April 2005

0 references

published in

0 references

cites work

Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Irritable colon and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

A Clinical Trial of Trimebutine (Mebutin) in Spastic Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Double blind study of ispaghula in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Symptom relief with amitriptyline in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Indications for prescription of fibre-rich nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Irritable bowel syndrome--role of motility inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

A Trial of Trimebutine in Spastic Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

A three-part controlled study of trimebutine in the treatment of irritable colon syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Controlled Clinical Trial of Sedative-Anticholinergic Drugs in Patients with the Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Effects of trimebutine on colonic function in patients with chronic idiopathic constipation: evidence for the need of a physiologic rather than clinical selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Therapeutic usefulness of amitriptyline in spastic colon syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

How to deal with chronic constipation. A stepwise method of establishing and treating the source of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Treatment of irritable bowel syndrome: a review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Different dietary fibre formulations and the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Fenfluramine challenge test predicts outcome in pharmacological treatment of patients with functional gastrointestinal disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Peppermint oil and colon spasm

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

A controlled therapeutic study of the irritable-bowel syndrome: effect of diphenylhydantoin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Bran supplementation in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

Treating irritable bowel syndrome with peppermint oil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021

The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB2

7 January 2021